メインコンテンツにスキップ

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2 inhibitor, across multiple cancer types, including relapsed and refractory (R/R) myelofibrosis (MF), Merkel cell carcinoma (MCC), and other malignancies. Using a PK model based on 318 subjects, researchers found that tumor type influenced navtemadlin’s absorption, clearance, and exposure, with factors … Continued

Understanding Variability in CAR-T Cell Therapy Kinetics

Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates substantial inter-individual variability in cellular kinetics. This variability complicates predicting therapeutic outcomes and managing associated toxicities, such as cytokine release syndrome (CRS) and neurological events (NEs). Identifying factors that influence CAR-T kinetics is critical for optimizing treatment and improving patient … Continued

1 of 10
Powered by Translations.com GlobalLink Web Software